What is RA Phase 2-3 Study Tasocitinib (CP-690,550)?

Category: Others

false

See also: Clinical Trial

NCT00413699 is a long-term, open-label follow-up study of tasocitinib (CP-690,550) for treatment of rheumatoid arthritis. Other study IDs include: A3921024.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 0
Moderate 0
Mild 0
None 1

Commonly reported side effects and conditions associated with RA Phase 2-3 Study Tasocitinib (CP-690,550)

Side effect Patients Percentage
Adherence
Adherence Evaluations Percentage
Always 1
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations Percentage
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 1
Cost per month
Cost per month Evaluations Percentage
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 1
Not specified 0
Last updated:
There are no evaluations for RA Phase 2-3 Study Tasocitinib (CP-690,550).